Bayles M A
Department of Dermatology, King Edward VIII Hospital and Medical School, University of Natal, Congella, Durban, South Africa.
Med Klin (Munich). 1991 Dec;86 Suppl 1:13-9.
The most common tropical subcutaneous and deep mycoses include chromomycosis, sporotrichosis and mycetoma. All are commonly found in Natal and in other sub-tropical countries. Although blastomycosis is endemic in North America, only four cases have been identified in Natal during the last 25 years and all presented with atypical clinical features. African histoplasmosis caused by H. capsulatum var. duboisii and limited mainly to central and western Africa has been found in only one patient in Natal. Paracoccidioidomycosis, although the most common deep mycosis in Latin America, is limited to that area and we have no experience of this disease in South Africa. Over the past eight years itraconazole has been used in clinical trials for all these mycoses. The results in sporotrichosis, non-meningeal blastomycosis and paracoccidioidomycosis suggest that for these diseases itraconazole may be the drug of choice. The results in histoplasmosis are encouraging as are the results in chromomycosis particularly those cases associated with C. carrionii. However, where F. pedrosoi is the causal agent and in mycetomas, successful management still remains a therapeutic problem. In our own experience and that of other using itraconazole, even over prolonged periods, this drug has an impressive safety profile. In our present series of 42 patients, no side effects were observed, no adverse reactions occurred and serum chemistry values remained within normal limits. It appears, therefore, that itraconazole, although not the final answer to management of the deep mycoses, is certainly a major improvement on previous drugs.
最常见的热带皮下和深部真菌病包括着色芽生菌病、孢子丝菌病和足菌肿。所有这些疾病在纳塔尔及其他亚热带国家都很常见。虽然芽生菌病在北美为地方病,但在过去25年里纳塔尔仅确诊4例,且所有病例均表现出非典型临床特征。由荚膜组织胞浆菌杜波依斯变种引起、主要局限于非洲中部和西部的非洲组织胞浆菌病,在纳塔尔仅在1例患者中发现。副球孢子菌病虽然是拉丁美洲最常见的深部真菌病,但仅限于该地区,我们在南非没有这种疾病的诊治经验。在过去八年中,伊曲康唑已用于所有这些真菌病的临床试验。孢子丝菌病、非脑膜芽生菌病和副球孢子菌病的试验结果表明,对于这些疾病,伊曲康唑可能是首选药物。组织胞浆菌病的试验结果令人鼓舞,着色芽生菌病的结果也是如此,尤其是与卡里尼氏支孢霉相关的病例。然而,对于以佩德罗索支孢霉为病原体的病例以及足菌肿,成功治疗仍然是一个治疗难题。根据我们自己以及其他使用伊曲康唑者的经验,即使长期使用,该药的安全性也令人印象深刻。在我们目前的42例患者系列中,未观察到副作用,未发生不良反应,血清化学值保持在正常范围内。因此,伊曲康唑虽然不是深部真菌病治疗的最终答案,但肯定比以前的药物有了重大改进。